FDA 483 OBSERVATION · #101 OF 1,923 MOST-CITED
Process control procedures, Lack of or inadequate procedures
FDA cited this observation 294 times across 276 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The device manufacturer lacked adequate production and process-control procedures, so processes that could affect device quality were not controlled to ensure conformance to specifications.
Why FDA writes it — Where device quality depends on the process, the process must be controlled. Inadequate process controls mean variation goes unmanaged and nonconforming devices are produced — so FDA cites weak production/process control as a direct route to defective product.
- Develop, conduct, control, and monitor production processes to ensure a device conforms to its specifications.
- Where deviations could occur, use documented procedures, defined process parameters and controls, and appropriate monitoring.
- Validate processes whose results cannot be fully verified by later inspection and test.
- Control changes to processes and assess their effect on device quality.
- Process parameters that matter for quality are not defined, controlled, or monitored.
- Processes needing validation are relied on without it.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.4× the rate of the average FDA-cited firm (10.9% vs 7.8%), across 276 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been established.
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.
Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →